Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opening Session Panel Discussion

Jul

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opening Session Panel Discussion

Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy

Beth Erickson, MD, FASTRO, Named ASTRO President-Elect

Monica Baskin Named Director of VCU Massey Comprehensive Cancer Center

Case Series Supports High-Dose Oral Vitamin D for Cancer Therapy–Related Skin Toxicities

MRI-Based T Staging Matches Traditional Clinical Staging in Localized Prostate Cancer